Evotec (NASDAQ:EVO – Get Free Report) had its price target dropped by stock analysts at HC Wainwright from $11.00 to $8.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 150.78% from the company’s current price.
Other analysts also recently issued reports about the company. Morgan Stanley downgraded Evotec from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th.
Check Out Our Latest Stock Analysis on EVO
Evotec Stock Down 3.6 %
Institutional Investors Weigh In On Evotec
Hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC bought a new stake in shares of Evotec in the 4th quarter valued at about $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec in the 2nd quarter valued at about $87,000. Cetera Advisors LLC bought a new stake in shares of Evotec in the 1st quarter valued at about $188,000. DCF Advisers LLC lifted its stake in shares of Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after acquiring an additional 67,156 shares during the last quarter. Finally, Optiver Holding B.V. lifted its stake in shares of Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the last quarter. Institutional investors own 5.81% of the company’s stock.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
- Five stocks we like better than Evotec
- What is Short Interest? How to Use It
- Jeff Brown’s Exegesis AI Stock Picks
- When to Sell a Stock for Profit or Loss
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
- What is MarketRank™? How to Use it
- Walmart Stock: Buy the Rip or Wait for the Dip?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.